Boehringer Ingelheim’s long-awaited phase 3 lung disease data received a muted reception from analysts who labeled nerandomilast “a step forward but not game-changing.” Boehringer revealed ...

Tata Motors Ltd. key Products/Revenue Segments include Motor Vehicles, Spare Parts & Others, Miscellaneous Goods, Sale of services and Other Operating Revenue for the year ending 31-Mar-2024.For the ...